Iambic Therapeutics
IAM
Dilution Known so far: 9.4M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM. Every source
Every Iambic Therapeutics filing is below, newest first.
Insiders 1 insider bought $11.5M of Iambic Therapeutics stock on the open market in the last 90 days. Every trade
IPO registration
Priced and listed · S-1/A filed Oct 8, 2026
- Amended registration S-1/AFirst filing
All filings
Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.
No IAM filings found yet.
Possible new shares
Known so far: 9.4M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM.
- 9.4M new shares from the 424B4 of Oct 15, 2026
Not read yet: warrants, convertible notes, options and RSUs and an ATM program.
Listing compliance
No listing notices in the 8-K item 3.01 filings SEC Tracker has read.
Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices
Trading halts
No trading halts for IAM since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.
Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts
Insiders
Show the latest Form 4 trade
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.
| Traded | Insider | Trade | Value | Stake | Notes |
|---|---|---|---|---|---|
| Oct 16, 2026 Filed Oct 19, 2026 | Evan Lockwood Rachlin Director | Bought in the offering 718,750 shares | $11.5M at $16.00 | +38% | At the offering price, the day after the 424B4. |
Open-market buys and sales (Form 4 codes P and S); planned sales are marked under a Rule 10b5-1 plan. Values as stated in each Form 4. Not investment advice. Every Form 4 for IAM · Insider trades across companies
Iambic Therapeutics shares and listing
From the company's own filings; each row names its source. Not investment advice.
- Listing compliance8-K item 3.01No noticesin the filings read
Insider activity
1 insider bought $11.5M of Iambic Therapeutics stock on the open market in the last 90 days.
- Director bought $11.5M